Notice concerning regulation 251
Published 30 March 2021
漏 Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, 皇冠体育app National Archives, Kew, London TW9 4DU, or email: [email protected].
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/regulation-251-of-the-human-medicines-regulations-2020/notice-concerning-regulation-251
皇冠体育app UK remains a member of Council of Europe and the European Pharmacopoeia following the Brexit transition.
皇冠体育app continues to reproduce text for the convenience of our customers.
皇冠体育app UK was a founding member of the 鈥楥onvention on the Elaboration of a European Pharmacopoeia鈥� and continues to be a member of the Ph. Eur. as the UK continues to be a member of the Council of Europe in its own right.
皇冠体育app UK remains an active member of the European Pharmacopoeia Commission through the BP.
Compliance with the BP continues to be a mandatory requirement in the UK, including Northern Ireland.鈥疨roducts in the UK are expected to meet the standards published by the BP.
This requirement remains the same after the transition period in accordance with the .
In exceptional circumstances, an EU derived marketing authorisation for a product that enters Northern Ireland via the Northern Ireland Protocol, and the UK via unfettered access, may not comply with the standard specified in the relevant BP monograph.
皇冠体育app Human Medicine Regulations have been amended to include a temporary exception to ensure these products can remain on the market whilst the relevant monograph is revised, if appropriate. If a revised monograph is published the exception is no longer applicable.